Inactive Instrument

Other languages Ceapro Inc Toronto S.E.

Equities

CZO

CA1499071076

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.	06-02
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	05-29
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	03-27
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	12-14
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	12-13
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	12-13
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	11-27
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	11-27
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	11-07
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	23-08-25
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	23-08-25
Ceapro Inc. Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	23-07-18
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director	23-06-07
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases	23-05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ceapro Inc Toronto S.E.

Equities

CZO

CA1499071076

Other languages

Filters